4th Quarter - Report — GILEAD SCIENCES, INC. for GILEAD SCIENCES INC (2021)

Firm

GILEAD SCIENCES, INC.

Client

GILEAD SCIENCES INC

Income

—

Expenses

$1,980,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Proposals to change corporate tax rates and related laws as part of budget reconciliation process.

Lobbyist	Covered position, as disclosed
CHARLES M. CLAPTON	—
DAVID PULLIAM	—

Contacted: Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Commerce, Dept of (DOC); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); White House Office; State, Dept of (DOS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries.

Lobbyist	Covered position, as disclosed
MICHAEL D BOYD	—
CHARLES M. CLAPTON	—
DAVID PULLIAM	—

Contacted: Office of Management & Budget (OMB); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Office of the Vice President of the United States; SENATE; Patent & Trademark Office (PTO); State, Dept of (DOS); Commerce, Dept of (DOC); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office

Copyright/Patent/Trademark CPT

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

Lobbyist	Covered position, as disclosed
JENNIFER NIETO CAREY	—
CHARLES M. CLAPTON	—
DAVID PULLIAM	—

Contacted: Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; State, Dept of (DOS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Natl Institutes of Health (NIH); Commerce, Dept of (DOC); Centers For Disease Control & Prevention (CDC); White House Office; Food & Drug Administration (FDA)

Health Issues HCR

Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).

Lobbyist	Covered position, as disclosed
TERESA BILL	—
MICHAEL D BOYD	—
JENNIFER NIETO CAREY	—
CHARLES M. CLAPTON	—
ANNA GRIFFIN	—
DAVID PULLIAM	—
GRACE RODDEN	—

Contacted: Office of the Vice President of the United States; SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); Commerce, Dept of (DOC); White House Office; State, Dept of (DOS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements.

Lobbyist	Covered position, as disclosed
TERESA BILL	—
MICHAEL D BOYD	—
JENNIFER NIETO CAREY	—
CHARLES M. CLAPTON	—
ANNA GRIFFIN	—
DAVID PULLIAM	—
GRACE RODDEN	—

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Office of the Vice President of the United States; Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Centers For Disease Control & Prevention (CDC); State, Dept of (DOS); Office of Management & Budget (OMB); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH)

Budget/Appropriations BUD

Funding for Hepatitis C, HIV, and public health activities via appropriations. Advocate on drug pricing proposals, including reconciliation legislation.

Lobbyist	Covered position, as disclosed
TERESA BILL	—
JENNIFER NIETO CAREY	—
CHARLES M. CLAPTON	—
DAVID PULLIAM	—
GRACE RODDEN	—

Contacted: Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); Office of the Vice President of the United States; Commerce, Dept of (DOC); White House Office; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); State, Dept of (DOS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.